Ovasave, a Hub71-backed FemTech startup focused on fertility and hormonal health, has successfully closed a $1.2 million pre-seed funding round to scale its services across the MENA region.
The round drew participation from leading regional and global investors, including PlusVC, Annex Investments, and New York-based 25 Madison, as well as UAE- and Saudi-based strategic angel investors and family offices.
The raise reflects growing investor confidence in women’s health innovation and rising demand for personalised, tech-enabled reproductive care in the Middle East.
Founded in 2023, Ovasave offers a digital-first platform combining at-home hormone testing, virtual consultations, supplement protocols, and access to leading fertility clinics, addressing key gaps in fertility testing, egg freezing, hormonal care, and menopause support.
The company also provides corporate fertility benefits, enabling employers to support reproductive health as part of workplace wellbeing programmes.
Funding to Fuel GCC Expansion and App Rollout
With this funding, Ovasave plans to accelerate its expansion into Saudi Arabia and the wider GCC, scale its corporate partnerships, and launch the next phase of its mobile app, which will include menstrual tracking, symptom monitoring, access to care, and AI-driven treatment protocols.
The platform is also widening its scope to cover historically overlooked stages of women’s health—perimenopause and menopause—where treatment gaps remain significant.
“There is a critical need for early and accessible intervention in women’s health, especially in fertility and hormone management,” said Torkia Mahloul, Co-founder and CEO of Ovasave. “This raise is a major milestone that enables us to scale our impact and empower women across life stages.”
A Strategic Moment for FemTech in the UAE
Ovasave’s growth aligns with broader healthcare reforms in the UAE and Abu Dhabi’s push toward preventive and digital health solutions.
The company is registered with the Department of Health, Abu Dhabi and supported by the Hub71 global tech ecosystem, positioning it to benefit from regulatory and innovation incentives.
“Abu Dhabi’s focus on healthcare innovation has created a competitive environment for FemTech founders,” added Majd Abu Zant, Co-founder and global expert in fertility healthcare.
“Proximity to regulators, investors, and healthcare partners gives us the ideal launchpad to scale regionally.”
According to a 2021 report by FemTech Analytics, the MENA FemTech market is expected to grow to $3.8 billion by 2031, at a 15% CAGR, underscoring the sector’s massive, untapped potential.
Breaking Taboos, Driving Awareness
Beyond clinical care, Ovasave is helping reshape the regional conversation around fertility and hormonal health, subjects still considered taboo in many communities.
The startup’s “Fertility Your Way” campaign with Merck Gulf provided free AMH hormone screenings to over 500 women across the UAE. It has also partnered with employers such as Aldar, Boston Consulting Group, and WeWork to raise awareness around fertility in the workplace.
“Women’s health is no longer a peripheral issue,” Mahloul said. “With investor backing and public demand, we’re witnessing a major shift—fertility and hormonal care are becoming core to both healthcare and innovation.”
